- The cost of the opioid epidemic in the US is 2.8% of GDP and has coincided with a decline in labor force participation
- Companies face multiple lawsuits from cities and states – which could potentially result in billions
- Opioid over-prescription (66.5 scrips per 100 Americans) at crisis level, but millions with chronic pain seek Alternatives in penalties
--> Teva, Insys, Cephalon, J&J, Janssen, Endo, Allergan, Watson, McKesson, Cardinal Health, and Amerisource